Intercept: FDA pushes back PDUFA dates for Amgen and Intercept

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen's Lumakras in metastatic colorectal cancer and Intercept Pharmaceuticals' Ocaliva for primary biliary cholangitis.The post FDA pushes back PDUFA dates for Amgen and Intercept appeared first on PharmaLive.